Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 15/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 7/20 | 0.49 |
| ▸ | PRKCH | P24723 | 1/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2125314 | 0.94 | PRKCQ (0.54) | PRKCQPRKCDPRKCHPRKCESYK | |
| SCHEMBL2123485 | 0.92 | PRKCQ (0.45) | PRKCQPRKCDPRKCHPRKCESYK | |
| SCHEMBL2127210 | 0.87 | PRKCQ (0.42) | PRKCQPRKCDPRKCHPRKCESYK | |
| SCHEMBL2125606 | 0.85 | CSNK2A1 (0.45) | PRKCQPRKCDPRKCHPRKCECSNK2A1 | |
| SCHEMBL2124161 | 0.84 | PRKCQ (0.46) | PRKCQPRKCDPRKCHPRKCECSNK2A1 | |
| SCHEMBL2125701 | 0.84 | CSNK2A1 (0.44) | PRKCQPRKCDPRKCHPRKCECSNK2A1 | |
| SCHEMBL2122644 | 0.84 | PRKCQ (0.43) | PRKCQPRKCDPRKCHPRKCECSNK2A1 | |
| SCHEMBL2123111 | 0.84 | CSNK2A1 (0.47) | PRKCQPRKCDPRKCHPRKCECSNK2A1 | |
| SCHEMBL2124008 | 0.83 | PRKCQ (0.44) | PRKCQPRKCDPRKCHPRKCECSNK2A1 | |
| SCHEMBL2124285 | 0.83 | PRKCQ (0.47) | PRKCQPRKCDPRKCHPRKCECSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | claimed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | claimed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | claimed |
| EP-2827890-B1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | UNIV QUEENSLAND (AU) | 2019-08-28 | — | — | EP | disclosed |
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20150216955-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-08-06 | — | — | US | disclosed |
| EP-2827890-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | The University of Queensland (AU) | 2015-01-28 | — | — | EP | disclosed |
| WO-2013138871-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-09-26 | — | — | WO | disclosed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2443123-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | Rigel Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010147898-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216955-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | HLA-DRB1, CD74, CHI3L1 | PRKCQ 3208/4885PRKCD 4471/4885PRKCH 3940/4885 |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | SYK, BTK, LCK | PRKCQ 112/4885PRKCD 492/4885PRKCH 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.